Distinct sensitivity and recovery of Res-TAMs and MoD-TAMs after chemotherapy. (A) Impact of CP treatment on tumor growth was monitored by bioluminescence imaging (graph represents mean ± SEM of n = 10 mice per group out of three independent experiments). (B) Dot plots show Ly6C and CD64 expressions of Siglec-F⁻CD11b⁺Ly6G⁻ lung cells over time after CP treatment. Mean percentage ± SD of cells in each quadrant are indicated. (C) Blood/tissue partitioning monitoring of lung monocytes and macrophages during tumor growth after chemotherapy (graphs represent mean of the absolute number ± SEM/milligram of tissue, n = 6–10 mice per time point out of two to four independent experiments, two-way ANOVA with Bonferroni multiple comparisons test was performed. Only statistical differences compared with day of treatment [day 0] are indicated for each compartment). (D) Graph shows the absolute number per milligram of tissue of ECFP⁺-TAMs and EGFP⁺-TAMs from MacBlue × Cx3cr1^EGFP/+ mice after CP (n = 4–10 mice per time point out of three independent experiments, two-way ANOVA with Bonferroni multiple comparisons test was performed). (E) Lung cryo-sections of TC-1^tdTomato tumor-bearing MacBlue × Cx3cr1^EGFP/+ mice show TAM subset distribution within tumor nodules following CP treatment. (F) Dot plots show TC-1^tdTomato phagocytosis by the indicated mononuclear phagocyte subsets (red). Fluorescent background from nonfluorescent TC-1 tumor is overlaid (left panels; black). Box and whisker graphs show the relative proportion of phagocytic cells among indicated subsets at 10 and 15 d after CP treatment (right panels; n = 9 mice out of three independent experiments). For all panels: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. See also Fig. S4.